Impact of Tofacitinib on Components of the ACR Response Criteria: Posthoc Analysis of Phase III and Phase IIIb/IV Trials

Funding: This study was sponsored by Pfizer Inc. Medical writing support, under the guidance of the authors, was provided by Jennifer Arnold, PhD, CMC Connect, McCann Health Medical Communications and was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015;163:461–464). L. Bessette, MD, MSc, Associate Professor, Department of Medicine, Laval University, Quebec, Quebec, Canada; E. Mysler, MD, Director, Organización Médica de Investigación, Buenos Aires, Argentina; C.D. Kinch, PhD, Medical Advisor, P.V. On, MSc, Senior Manager Access, Pfizer Canada ULC, Kirkland, Quebec, Canada; K. Kwok, MS, Senior Director, T. Lukic, MD, MSc, Global Clinical Lead, Pfizer Inc, New York, New York, USA;5R.F. van Vollenhoven, MD, PhD, Director, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands; R.F. van Vollenhoven, MD, PhD, Professor and Chair, Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centres, Amsterdam, The Netherlands. Conflict of Interest: LB has received grants and/or research support from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Eli Lilly, Gilead Sciences, Novartis, Pfizer Inc, Roche, Sanofi, and UCB; and has acted as a consultant or speaker for AbbVie, Celgene, Eli Lilly, Fresenius Kabi, Gilead Sciences, Novartis, Pfizer Inc, and Sandoz. EM has received research grants from Eli Lilly, Pfizer Inc, and Roche; and serves on speakers' bureaus for AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen, Pfizer Inc, Roche, and Sanofi. CDK, KK, TL, and PVO are employees and stockholders of Pfizer Inc. RFvV has received grants and/or research support from AbbVie, Amgen, Bristol-Myers Squibb, GSK, Pfizer Inc, Roche, and UCB; and has acted as a consultant for AbbVie, AstraZeneca, Biotest, Bristol- Myers Squibb, Celgene, Crescendo, Eli Lilly, GSK, Janssen, Merck, Novartis, Pfizer Inc, Roche, UCB, and Vertex. Address correspondence to C. D Kinch, Pfizer Canada ULC, 17300 Trans-Canada Hwy, Kirkland, QC, Canada H9J2M5. Telephone: 403-827-3347. Email: Cassandra.Kinch@pfizer.com.

Funding: This study was sponsored by Pfizer Inc. Medical writing support, under the guidance of the authors, was provided by Jennifer Arnold, PhD, CMC Connect, McCann Health Medical Communications and was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015;163:461–464). L. Bessette, MD, MSc, Associate Professor, Department of Medicine, Laval University, Quebec, Quebec, Canada; E. Mysler, MD, Director, Organización Médica de Investigación, Buenos Aires, Argentina; C.D. Kinch, PhD, Medical Advisor, P.V. On, MSc, Senior Manager Access, Pfizer Canada ULC, Kirkland, Quebec, Canada; K. Kwok, MS, Senior Director, T. Lukic, MD, MSc, Global Clinical Lead, Pfizer Inc, New York, New York, USA;5R.F. van Vollenhoven, MD, PhD, Director, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands; R.F. van Vollenhoven, MD, PhD, Professor and Chair, Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centres, Amsterdam, The Netherlands. Conflict of Interest: LB has received grants and/or research support from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Eli Lilly, Gilead Sciences, Novartis, Pfizer Inc, Roche, Sanofi, and UCB; and has acted as a consultant or speaker for AbbVie, Celgene, Eli Lilly, Fresenius Kabi, Gilead Sciences, Novartis, Pfizer Inc, and Sandoz. EM has received research grants from Eli Lilly, Pfizer Inc, and Roche; and serves on speakers' bureaus for AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen, Pfizer Inc, Roche, and Sanofi. CDK, KK, TL, and PVO are employees and stockholders of Pfizer Inc. RFvV has received grants and/or research support from AbbVie, Amgen, Bristol-Myers Squibb, GSK, Pfizer Inc, Roche, and UCB; and has acted as a consultant for AbbVie, AstraZeneca, Biotest, Bristol- Myers Squibb, Celgene, Crescendo, Eli Lilly, GSK, Janssen, Merck, Novartis, Pfizer Inc, Roche, UCB, and Vertex. Address correspondence to C. D Kinch, Pfizer Canada ULC, 17300 Trans-Canada Hwy, Kirkland, QC, Canada H9J2M5. Telephone: 403-827-3347. Email: Cassandra.Kinch@pfizer.com.

Funding: This study was sponsored by Pfizer Inc. Medical writing support, under the guidance of the authors, was provided by Jennifer Arnold, PhD, CMC Connect, McCann Health Medical Communications and was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015;163:461–464). L. Bessette, MD, MSc, Associate Professor, Department of Medicine, Laval University, Quebec, Quebec, Canada; E. Mysler, MD, Director, Organización Médica de Investigación, Buenos Aires, Argentina; C.D. Kinch, PhD, Medical Advisor, P.V. On, MSc, Senior Manager Access, Pfizer Canada ULC, Kirkland, Quebec, Canada; K. Kwok, MS, Senior Director, T. Lukic, MD, MSc, Global Clinical Lead, Pfizer Inc, New York, New York, USA;5R.F. van Vollenhoven, MD, PhD, Director, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands; R.F. van Vollenhoven, MD, PhD, Professor and Chair, Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centres, Amsterdam, The Netherlands. Conflict of Interest: LB has received grants and/or research support from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Eli Lilly, Gilead Sciences, Novartis, Pfizer Inc, Roche, Sanofi, and UCB; and has acted as a consultant or speaker for AbbVie, Celgene, Eli Lilly, Fresenius Kabi, Gilead Sciences, Novartis, Pfizer Inc, and Sandoz. EM has received research grants from Eli Lilly, Pfizer Inc, and Roche; and serves on speakers' bureaus for AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen, Pfizer Inc, Roche, and Sanofi. CDK, KK, TL, and PVO are employees and stockholders of Pfizer Inc. RFvV has received grants and/or research support from AbbVie, Amgen, Bristol-Myers Squibb, GSK, Pfizer Inc, Roche, and UCB; and has acted as a consultant for AbbVie, AstraZeneca, Biotest, Bristol- Myers Squibb, Celgene, Crescendo, Eli Lilly, GSK, Janssen, Merck, Novartis, Pfizer Inc, Roche, UCB, and Vertex. Address correspondence to C. D Kinch, Pfizer Canada ULC, 17300 Trans-Canada Hwy, Kirkland, QC, Canada H9J2M5. Telephone: 403-827-3347. Email: Cassandra.Kinch@pfizer.com.

Funding: This study was sponsored by Pfizer Inc. Medical writing support, under the guidance of the authors, was provided by Jennifer Arnold, PhD, CMC Connect, McCann Health Medical Communications and was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015;163:461–464). L. Bessette, MD, MSc, Associate Professor, Department of Medicine, Laval University, Quebec, Quebec, Canada; E. Mysler, MD, Director, Organización Médica de Investigación, Buenos Aires, Argentina; C.D. Kinch, PhD, Medical Advisor, P.V. On, MSc, Senior Manager Access, Pfizer Canada ULC, Kirkland, Quebec, Canada; K. Kwok, MS, Senior Director, T. Lukic, MD, MSc, Global Clinical Lead, Pfizer Inc, New York, New York, USA;5R.F. van Vollenhoven, MD, PhD, Director, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands; R.F. van Vollenhoven, MD, PhD, Professor and Chair, Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centres, Amsterdam, The Netherlands. Conflict of Interest: LB has received grants and/or research support from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Eli Lilly, Gilead Sciences, Novartis, Pfizer Inc, Roche, Sanofi, and UCB; and has acted as a consultant or speaker for AbbVie, Celgene, Eli Lilly, Fresenius Kabi, Gilead Sciences, Novartis, Pfizer Inc, and Sandoz. EM has received research grants from Eli Lilly, Pfizer Inc, and Roche; and serves on speakers' bureaus for AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen, Pfizer Inc, Roche, and Sanofi. CDK, KK, TL, and PVO are employees and stockholders of Pfizer Inc. RFvV has received grants and/or research support from AbbVie, Amgen, Bristol-Myers Squibb, GSK, Pfizer Inc, Roche, and UCB; and has acted as a consultant for AbbVie, AstraZeneca, Biotest, Bristol- Myers Squibb, Celgene, Crescendo, Eli Lilly, GSK, Janssen, Merck, Novartis, Pfizer Inc, Roche, UCB, and Vertex. Address correspondence to C. D Kinch, Pfizer Canada ULC, 17300 Trans-Canada Hwy, Kirkland, QC, Canada H9J2M5. Telephone: 403-827-3347. Email: Cassandra.Kinch@pfizer.com.

Funding: This study was sponsored by Pfizer Inc. Medical writing support, under the guidance of the authors, was provided by Jennifer Arnold, PhD, CMC Connect, McCann Health Medical Communications and was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015;163:461–464). L. Bessette, MD, MSc, Associate Professor, Department of Medicine, Laval University, Quebec, Quebec, Canada; E. Mysler, MD, Director, Organización Médica de Investigación, Buenos Aires, Argentina; C.D. Kinch, PhD, Medical Advisor, P.V. On, MSc, Senior Manager Access, Pfizer Canada ULC, Kirkland, Quebec, Canada; K. Kwok, MS, Senior Director, T. Lukic, MD, MSc, Global Clinical Lead, Pfizer Inc, New York, New York, USA;5R.F. van Vollenhoven, MD, PhD, Director, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands; R.F. van Vollenhoven, MD, PhD, Professor and Chair, Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centres, Amsterdam, The Netherlands. Conflict of Interest: LB has received grants and/or research support from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Eli Lilly, Gilead Sciences, Novartis, Pfizer Inc, Roche, Sanofi, and UCB; and has acted as a consultant or speaker for AbbVie, Celgene, Eli Lilly, Fresenius Kabi, Gilead Sciences, Novartis, Pfizer Inc, and Sandoz. EM has received research grants from Eli Lilly, Pfizer Inc, and Roche; and serves on speakers' bureaus for AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen, Pfizer Inc, Roche, and Sanofi. CDK, KK, TL, and PVO are employees and stockholders of Pfizer Inc. RFvV has received grants and/or research support from AbbVie, Amgen, Bristol-Myers Squibb, GSK, Pfizer Inc, Roche, and UCB; and has acted as a consultant for AbbVie, AstraZeneca, Biotest, Bristol- Myers Squibb, Celgene, Crescendo, Eli Lilly, GSK, Janssen, Merck, Novartis, Pfizer Inc, Roche, UCB, and Vertex. Address correspondence to C. D Kinch, Pfizer Canada ULC, 17300 Trans-Canada Hwy, Kirkland, QC, Canada H9J2M5. Telephone: 403-827-3347. Email: Cassandra.Kinch@pfizer.com.

Funding: This study was sponsored by Pfizer Inc. Medical writing support, under the guidance of the authors, was provided by Jennifer Arnold, PhD, CMC Connect, McCann Health Medical Communications and was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015;163:461–464). L. Bessette, MD, MSc, Associate Professor, Department of Medicine, Laval University, Quebec, Quebec, Canada; E. Mysler, MD, Director, Organización Médica de Investigación, Buenos Aires, Argentina; C.D. Kinch, PhD, Medical Advisor, P.V. On, MSc, Senior Manager Access, Pfizer Canada ULC, Kirkland, Quebec, Canada; K. Kwok, MS, Senior Director, T. Lukic, MD, MSc, Global Clinical Lead, Pfizer Inc, New York, New York, USA;5R.F. van Vollenhoven, MD, PhD, Director, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands; R.F. van Vollenhoven, MD, PhD, Professor and Chair, Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centres, Amsterdam, The Netherlands. Conflict of Interest: LB has received grants and/or research support from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Eli Lilly, Gilead Sciences, Novartis, Pfizer Inc, Roche, Sanofi, and UCB; and has acted as a consultant or speaker for AbbVie, Celgene, Eli Lilly, Fresenius Kabi, Gilead Sciences, Novartis, Pfizer Inc, and Sandoz. EM has received research grants from Eli Lilly, Pfizer Inc, and Roche; and serves on speakers' bureaus for AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen, Pfizer Inc, Roche, and Sanofi. CDK, KK, TL, and PVO are employees and stockholders of Pfizer Inc. RFvV has received grants and/or research support from AbbVie, Amgen, Bristol-Myers Squibb, GSK, Pfizer Inc, Roche, and UCB; and has acted as a consultant for AbbVie, AstraZeneca, Biotest, Bristol- Myers Squibb, Celgene, Crescendo, Eli Lilly, GSK, Janssen, Merck, Novartis, Pfizer Inc, Roche, UCB, and Vertex. Address correspondence to C. D Kinch, Pfizer Canada ULC, 17300 Trans-Canada Hwy, Kirkland, QC, Canada H9J2M5. Telephone: 403-827-3347. Email: Cassandra.Kinch@pfizer.com.

Funding: This study was sponsored by Pfizer Inc. Medical writing support, under the guidance of the authors, was provided by Jennifer Arnold, PhD, CMC Connect, McCann Health Medical Communications and was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015;163:461–464). L. Bessette, MD, MSc, Associate Professor, Department of Medicine, Laval University, Quebec, Quebec, Canada; E. Mysler, MD, Director, Organización Médica de Investigación, Buenos Aires, Argentina; C.D. Kinch, PhD, Medical Advisor, P.V. On, MSc, Senior Manager Access, Pfizer Canada ULC, Kirkland, Quebec, Canada; K. Kwok, MS, Senior Director, T. Lukic, MD, MSc, Global Clinical Lead, Pfizer Inc, New York, New York, USA;5R.F. van Vollenhoven, MD, PhD, Director, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands; R.F. van Vollenhoven, MD, PhD, Professor and Chair, Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centres, Amsterdam, The Netherlands. Conflict of Interest: LB has received grants and/or research support from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Eli Lilly, Gilead Sciences, Novartis, Pfizer Inc, Roche, Sanofi, and UCB; and has acted as a consultant or speaker for AbbVie, Celgene, Eli Lilly, Fresenius Kabi, Gilead Sciences, Novartis, Pfizer Inc, and Sandoz. EM has received research grants from Eli Lilly, Pfizer Inc, and Roche; and serves on speakers' bureaus for AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen, Pfizer Inc, Roche, and Sanofi. CDK, KK, TL, and PVO are employees and stockholders of Pfizer Inc. RFvV has received grants and/or research support from AbbVie, Amgen, Bristol-Myers Squibb, GSK, Pfizer Inc, Roche, and UCB; and has acted as a consultant for AbbVie, AstraZeneca, Biotest, Bristol- Myers Squibb, Celgene, Crescendo, Eli Lilly, GSK, Janssen, Merck, Novartis, Pfizer Inc, Roche, UCB, and Vertex. Address correspondence to C. D Kinch, Pfizer Canada ULC, 17300 Trans-Canada Hwy, Kirkland, QC, Canada H9J2M5. Telephone: 403-827-3347. Email: Cassandra.Kinch@pfizer.com.